Tuesday, May 28, 2024
HomeHealth ConditionsCOVID-19Antibodies against original COVID-19 strain may not be effective against variants

Antibodies against original COVID-19 strain may not be effective against variants

The antibodies produced from the original COVID-19 virus strain are not equipped to fight against viral variants, a study suggests. 

The study, published in June, identified two gene sequences commonly found in antibodies against the virus that causes COVID-19.1 These gene sequences called “clonotypes” are part of the antibodies that bind to the spike protein. 

How do antibodies protect against COVID-19 infection?

The SAR-CoV-2 virus is covered with spike proteins that contain a receptor-binding domain (RBD). This domain or area binds to receptors on human cells to gain entry and cause infection.1 RBD antibodies bind to the RBD to prevent this interaction from happening. 

Both clonotypes identified by the research team are RBD antibodies that have a high frequency among public COVID-19 infections. 

​​“Antibody response is quite relevant to everything from understanding natural infection and how we recover from infection to vaccine design”, said Dr. Nicholas Wu, professor of biochemistry and co-author of the study. “That means we can design vaccines trying to elicit this kind of antibody response, and that is probably going to improve the responsiveness of more individuals to the vaccine.”2

Antibodies against variant COVID-19 strains differ

The study went on to compare the effectiveness of both clonotypes for the original SARS-CoV-2 strain to variant strains from South Africa and Brazil. These variants decreased the affinity of the clonotypes to the spike protein.1  

“Even though this antibody response is very common with the original strain, it doesn’t really interact with variants,” Dr. Wu commented.2 This finding suggests that new variants could reinfect individuals who have already had COVID-19. 

The varying immune response between strains emphasizes the potential need for a vaccine booster to combat new variant strains. However, more data needs to be collected to determine which immune response is needed to protect the majority of the population from COVID-19 infection.


  1. Tan, T.J.C. et al. (2021). Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nature Communications; 12:3815. Doi: 10.1038/s41467-021-24123-7. 
  2. Touchstone, L. (2021). Antibodies from original strain COVID-19 infection don’t bind to variants, study finds. EurekAlert! Accessed Sept 23, 2021. Retrieved from https://www.eurekalert.org/news-releases/928827. 
  3. Image by Gerd Altmann from Pixabay 
Bryn Evans
Bryn Evans
I graduated with a major in biochemistry, a minor in physics, and a certificate in business from Queen’s University. My long-term goal is to become a family physician (MD) and earn a Master’s in Public Health (MPH). I am passionate about public health, mental health, & wellness. I'm currently completing a Certificate in Effective Writing for Healthcare because I recognize how important it is to communicate effectively with the public!


Please enter your comment!
Please enter your name here

Latest News and Articles


Stay Connected

Article of the month

Recognizing HIE: A Call for Advocacy

Have you heard of HIE? It’s the second leading cause of infant mortality and lifelong disability worldwide. 2-3 per 1,000 live births in high-income...

Joke Of The Day – May 28

A medical student was visiting his elderly grandfather and was asking him about the new medication that he was currently taking. "So, I understand that...


error: Content is read-only and copy-protected.